Senate Health Cmte. Chairman Enzi Addresses FDLI April 7
This article was originally published in The Pink Sheet Daily
FDA drug safety issues are expected to highlight both Enzi’s and Commissioner-nominee Crawford’s keynote presentations. Additional speakers at the regulatory group’s annual meeting include CMS Administrator McClellan, HHS General Counsel Azar.
You may also be interested in...
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.